Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 2/3 1

Status

Completed 4Withdrawn 1

Sponsor Class

INDUSTRY 3OTHER 1NIH 1

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 5Gynecologic 5Gastrointestinal 5Breast 4Sarcoma 3Genitourinary 3Tumor-Agnostic 2Plasma cell 1Other solid neoplasm 1Head & Neck 1Dermatologic 1

Conditions

Ovarian Neoplasms 3Neoplasms 3Stomach Neoplasms 1Sarcoma, Endometrial Stromal 1Sarcoma 1Rhabdomyosarcoma 1Pancreatic Neoplasms 1Neoplasms, Plasma Cell 1Lung Neoplasms 1Liver Neoplasms 1Liposarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Fibrosarcoma 1Fallopian Tube Neoplasms 1Dermatofibrosarcoma 1Colonic Neoplasms 1Choriocarcinoma 1Cholangiocarcinoma 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Paclitaxel 575Carboplatin 520Cisplatin 347Bevacizumab 252pembrolizumab 226Gemcitabine 157Topotecan 128liposomal doxorubicin 127Cyclophosphamide 126olaparib 120Taxes 113Radiotherapy 110Docetaxel 94Brachytherapy 89Doxorubicin 84Drug Therapy 80niraparib 75Nivolumab 71Magnetic Resonance Spectroscopy 71Specimen Handling 65fludarabine 56Biopsy 55Hyperthermic Intraperitoneal Chemotherapy 53Filgrastim 52Letrozole 50Oxaliplatin 48durvalumab 47Immunoglobulin G 47atezolizumab 46Platinum 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × saracatinib × Gynecologic × Clear all
NCT00659360 2018-06-29

AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma

National Cancer Institute (NCI)

Phase 2 Completed
17 enrolled 9 charts
GynecologicSarcoma

Fibrosarcoma, Leiomyosarcoma, Liposarcoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Endometrial Stromal, Dermatofibrosarcoma, Histiocytoma, Malignant Fibrous

NCT01196741 2015-05-05

SaPPrOC

University College, London

Phase 2/3 Completed
107 enrolled 17 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00610714 2012-12-18

OVERT-1

AstraZeneca

Phase 2 Completed
211 enrolled 12 charts
Gynecologic

Neoplasms, Ovarian Neoplasms

NCT00475956 2010-04-15

Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours

AstraZeneca

Phase 1 Completed
40 enrolled
BreastGastrointestinalGynecologicPlasma cellThoracic

Breast Neoplasms, Choriocarcinoma, Colonic Neoplasms, Liver Neoplasms, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Cholangiocarcinoma, Neoplasms, Plasma Cell

NCT01000896 2010-02-04

Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and Paclitaxel

AstraZeneca

Phase 1 Withdrawn
27 enrolled
GynecologicThoracic

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡